Journal Watch · Leukemia · 2026

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.

These findings highlight <sup>Allo</sup>CAR70-NKT cells as a safe and powerful off-the-shelf immunotherapy that can synergize with HMAs to improve treatment outcomes for patients with AML.

Li YR, Shen X, Chen Y et al.Leukemia3 min readPharma relevance 75/100

DOI: 10.1038/s41375-026-02930-5PMID: 41888396Study type: preclinical (animal / model) study

TL;DR

These findings highlight <sup>Allo</sup>CAR70-NKT cells as a safe and powerful off-the-shelf immunotherapy that can synergize with HMAs to improve treatment outcomes for patients with AML.

Key findings

  • Both CAR70-NKT cell products exhibited potent cytotoxicity against AML cells and synergized with HMAs, while <sup>Allo</sup>CAR70-NKT cells demonstrated superior antitumor efficacy, multi-target recognition, and sustained expansion.
  • In multiple xenograft models, <sup>Allo</sup>CAR70-NKT cells effectively killed AML tumors without inducing graft-versus-host disease, cytokine release syndrome, or long-term organ toxicity.
  • These findings highlight <sup>Allo</sup>CAR70-NKT cells as a safe and powerful off-the-shelf immunotherapy that can synergize with HMAs to improve treatment outcomes for patients with AML.

What they did

In this study, we found that long-term, low-dose HMA treatment upregulated CD70, NK receptor ligands, and CD1d on AML tumor cells, rendering them more susceptible to chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-NKT) cell-mediated cytotoxicity. To exploit these features, we generated two types of CD70-targeting CAR-NKT cells: cord blood hematopoietic stem and progenitor cell (HSPC)-derived allogeneic CAR70-NKT (<sup>Allo</sup>CAR70-NKT) cells and peripheral blood mononuclear cell (PBMC)-derived CAR70-NKT (<sup>PBMC</sup>CAR70-NKT) cells.

Full abstract (original)

Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the uncontrolled expansion of undifferentiated myeloid precursors in the bone marrow. Hypomethylating agents (HMAs) such as azacitidine and decitabine can reverse abnormal DNA methylation, promote leukemic cell differentiation, and enhance immune recognition, yet relapse and therapeutic resistance remain major challenges.

What they did: In this study, we found that long-term, low-dose HMA treatment upregulated CD70, NK receptor ligands, and CD1d on AML tumor cells, rendering them more susceptible to chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-NKT) cell-mediated cytotoxicity. To exploit these features, we generated two types of CD70-targeting CAR-NKT cells: cord blood hematopoietic stem and progenitor cell (HSPC)-derived allogeneic CAR70-NKT (<sup>Allo</sup>CAR70-NKT) cells and peripheral blood mononuclear cell (PBMC)-derived CAR70-NKT (<sup>PBMC</sup>CAR70-NKT) cells.

Results & conclusions: Both CAR70-NKT cell products exhibited potent cytotoxicity against AML cells and synergized with HMAs, while <sup>Allo</sup>CAR70-NKT cells demonstrated superior antitumor efficacy, multi-target recognition, and sustained expansion. In multiple xenograft models, <sup>Allo</sup>CAR70-NKT cells effectively killed AML tumors without inducing graft-versus-host disease, cytokine release syndrome, or long-term organ toxicity. These findings highlight <sup>Allo</sup>CAR70-NKT cells as a safe and powerful off-the-shelf immunotherapy that can synergize with HMAs to improve treatment outcomes for patients with AML.

Abstract © the authors / Leukemia (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41375-026-02930-5 · PubMed 41888396.

Why it matters for pharma & biotech

  • Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: cell therapy (CAR-T / engineered cells)

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Leukemia study find?

These findings highlight <sup>Allo</sup>CAR70-NKT cells as a safe and powerful off-the-shelf immunotherapy that can synergize with HMAs to improve treatment outcomes for patients with AML.

What type of study is this?

It is a preclinical (animal / model) study, published in Leukemia in 2026. In this study, we found that long-term, low-dose HMA treatment upregulated CD70, NK receptor ligands, and CD1d on AML tumor cells, rendering them more susceptible to chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-NKT) cell-mediated cytotoxicity.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41375-026-02930-5. PubMed ID: 41888396. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Li YR, Shen X, Chen Y et al.. Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia.. Leukemia (2026). DOI: 10.1038/s41375-026-02930-5.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/synergizing-hypomethylating-agents-with-off-the-shelf-cd70-targeted-chim-029305/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides